Biochemistry of Hellp Syndrome

Advances in Clinical Chemistry

Volumn 53, Issue C, 2011, Pages 85-104

  Benedetto, Chiara ^a   Marozio, Luca ^a   Tancredi, Annalisa ^a   Picardo, Elisa ^a   Nardolillo, Paola ^a   Tavella, Anna Maria ^a   Salton, Loredana ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Coagulation system; Complement; HELLP syndrome; Inflammation; Severe preeclampsia

Indexed keywords

COMPLEMENT;

BLOOD CLOTTING; BOOK; FEMALE; HELLP SYNDROME; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PLACENTA; PREECLAMPSIA; PREGNANCY;

BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; FEMALE; HELLP SYNDROME; HUMANS; INFLAMMATION; PLACENTA; PRE-ECLAMPSIA; PREGNANCY;

EID: 78650990715     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385855-9.00004-7     Document Type: Book

References (102)

1. Stella C.L., Malik K.M., Sibai B.M. HELLP syndrome: an atypical presentation. Am. J. Obstet. Gynecol. 2008, 196:e6-e8.
2. Sibai B.M., Ramadan M.K., Usta I., Salama M., Mercer B.M., Friedman S.A. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am. J. Obstet. Gynecol. 1993, 169:1000-1006.
3. Magann E.F., Martin J.N. Twelve steps to optimal management of HELLP syndrome. Clin. Obstet. Gynecol. 1999, 42:532-550.
4. Sibai B.M. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet. Gynecol. 2004, 103:981-991.
5. Kawabata I., Nakai A., Takeshita T. Prediction of HELLP syndrome with assessment of maternal dual hepatic blood supply by using Doppler ultrasound. Arch. Gynecol. Obstet. 2006, 274:303-309.
6. O'Brien J.M., Burton J.R. Controversies with the diagnosis and management of HELLP syndrome. Clin. Obstet. Gynecol. 2005, 48:460-477.
7. Wust M.D., Bolte A.C., de Vries J.I., Dekker G.A., Cuesta M.A., van Geijn H.P. Pregnancy outcome after previous pregnancy complicated by hepatic rupture. Hypertens. Pregnancy 2004, 23:29-35.
8. Mihu D., Costin M., Mihu C.M., Seicean A., Ciortea R. HELLP syndrome-a multisystemic disorder. J. Gastrointest. Liver Dis. 2007, 16:419-424.
9. Baxter J.K., Weinstein L. HELLP syndrome: the state of the art. Obstet. Gynecol. Surv. 2004, 59:838-845.
10. Rath W., Faridi A., Dudenhausen J.W. HELLP syndrome. J. Perinat. Med. 2000, 28:249-260.
11. Wilke G., Rath W., Schutz E., Armstrong V.W., Kuhn W. Haptoglobin as a sensitive marker of hemolysis in HELLP-syndrome. Int. J. Gynaecol. Obstet. 1992, 39:29-34.
12. van Runnard Heimel P.J., Franx A., Schobben A.F., Huisjes A.J., Derks J.B., Bruinse H.W. Corticosteroids, pregnancy, and HELLP syndrome: a review. Obstet. Gynecol. Surv. 2005, 60:57-70.
13. Sibai B.M. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing?. Am. J. Obstet. Gynecol. 1990, 162:311-316.
14. Sibai B.M. Imitators of severe pre-eclampsia/eclampsia. Clin. Perinatol. 2004, 31:835-852.
15. Smulian J.C., Shen-Schwarz S., Scorza W.E., Kinzler W.L., Vintzileos A.M. A clinico-histopathological comparison between HELLP syndrome and severe preeclampsia. J. Matern. Fetal Neonatal Med. 2004, 16:287-293.
16. Visser W., Wallenburg H.C. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br. J. Obstet. Gynaecol. 1995, 102:111-117.
17. Parnas M., Sheiner E., Shoham-Vardi I., et al. Moderate to severe thrombocytopenia during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 128:163-168.
18. Sibai B.M. Imitators of severe pre-eclampsia. Semin. Perinatol. 2009, 33:196-205.
19. Fesenmeier M.F., Coppage K.H., Lambers D.S., et al. Acute fatty liver of pregnancy in 3 tertiary care centers. Am. J. Obstet. Gynecol. 2005, 192:1416-1419.
20. Knight M., Nelson-Piercy C., Kurinczuk J.J. On behalf of UK obstetric surveillance system (UKOSS), A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008, 57:951-956.
21. Rajasri A.G., Sretha R., Mitchell J. Acute fatty liver of pregnancy (AFLP): an overview. J. Obstet. Gynaecol. 2007, 27:237-240.
22. Araujo A.C., Leao M.D., Nobrega M.H., et al. Characteristics and treatment of hepatic rupture caused by HELLP syndrome. Am. J. Obstet. Gynecol. 2006, 195:129-133.
23. Wicke C., Pereira P.L., Neeser E., Flesch I., Rodegerdts E.A., Becker H.D. Subcapsular liver hematoma in HELLP syndrome: evaluation of diagnostic and therapeutic options-a unicenter study. Am. J. Obstet. Gynecol. 2004, 190:106-112.
24. Merchant S.H., Mathew P., Vanderjagt T.J., Howdieshell T.R., Crookston K.P. Recombinant factor VIIa in management of spontaneous subcapsular liver hematoma associated with pregnancy. Obstet. Gynecol. 2004, 103:1055-1058.
25. Stewart M.W., Brazis P.W., Guier C.P., Thota S.H., Wilson S.D. Purtscher-like retinopathy in a patient with HELLP syndrome. Am. J. Ophthalmol. 2007, 143:886-887.
26. Ertan A.K., Wagner S., Hendrik H.J., Tanriverdi H.A., Schmidt W. Clinical and biophysical aspects of HELLP-syndrome. J. Perinat. Med. 2002, 30:483-489.
27. Altamura C., Vasapollo B., Tibuzzi F., et al. Postpartum cerebellar infarction and haemolysis, elevated liver enzymes, low platelet (HELLP) syndrome. Neurol. Sci. 2005, 26:40-42.
28. Soh Y., Yasuhi I., Nakayama D., Ishimaru T. A case of postpartum cerebellar infarction with hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome. Gynecol. Obstet. Invest. 2002, 53:240-242.
29. Zeidman L.A., Videnovic A., Bernstein L.P., Pellar C.A. Lethal pontine hemorrhage in postpartum syndrome of hemolysis, elevated liver enzyme levels, and low platelet count. Arch. Neurol. 2005, 62:1150-1153.
30. Kittner S.J., Stern B.J., Feeser B.R., et al. Pregnancy and the risk of stroke. N. Engl. J. Med. 1996, 335:768-774.
31. Bick R.L. Syndromes of disseminated intravascular coagulation in obstetrics, pregnancy, and gynecology. Objective criteria for diagnosis and management. Hematol. Oncol. Clin. North Am. 2000, 14:999-1044.
32. Detti L., Mecacci F., Piccioli A., et al. Postpartum heparin therapy for patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) is associated with significant hemorrhagic complications. J. Perinatol. 2005, 25:236-240.
33. Martin J.N., Thigpen B.D., Rose C.H., Cushman J., Moore A., May W.L. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am. J. Obstet. Gynecol. 2003, 189:830-834.
34. Yücesoy G., Ozkan S., Bodur H., et al. Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Arch. Gynecol. Obstet. 2005, 273:43-49.
35. Isler C.M., Rinehart B.K., Terrone D.A., Martin R.W., Magann E.F., Martin J.N. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am. J. Obstet. Gynecol. 1999, 181:924-928.
36. Aslan H., Gul A., Cebeci A. Neonatal outcome in pregnancies after preterm delivery for HELLP syndrome. Gynecol. Obstet. Invest. 2004, 58:96-99.
37. Abramovici D., Friedman S.A., Mercer B.M., Audibert F., Kao L., Sibai B.M. Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter?. Am. J. Obstet. Gynecol. 1999, 180:221-225.
38. Gul A., Cebeci A., Aslan H., Polat I., Ozdemir A., Ceylan Y. Perinatal outcomes in severe preeclampsia-eclampsia with and without HELLP syndrome. Gynecol. Obstet. Invest. 2005, 59:113-118.
39. Osmanagaoglu M.A., Erdogan I., Zengin U., Bozkaya H. Comparison between HELLP syndrome, chronic hypertension, and superimposed preeclampsia on chronic hypertension without HELLP syndrome. J. Perinat. Med. 2004, 32:481-485.
40. Goldman-Whol D., Yagel S. Regulation of trophoblast invasion: from normal implantation to pre-eclampsia. Mol. Cell. Endocrinol. 2002, 187:233-238.
41. Kaufmann P., Black S., Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reprod. 2003, 69:1-7.
42. Sargent I.L., Borzychowski A.M., Redman C.W.G. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod. Biomed. Online 2006, 13:680-686.
43. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., Mclaughlin M.K. Preeclampsia-an endothelial-cell disorder. Am. J. Obstet. Gynecol. 1989, 161:1200-1204.
44. Chambers J.C., Fusi L., Malik I.S., Haskard D.O., de Swiet M., Kooner J.S. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001, 285:1607-1612.
45. Myers J., Mires G., Macleod M., Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005, 45:258-263.
46. Khalil R.A., Granger J.P. Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 283:R29-R45.
47. Roberts J.M., Hubel C.A. Is oxidative stress the link in the two-stage model of pre-eclampsia?. Lancet 1999, 354:788-789.
48. Many A., Hubel C.A., Fisher S.J., Roberts J.M., Zhou Y. Invasive cytotrophoblasts manifest evidence of oxidative stress in preeclampsia. Am. J. Pathol. 2000, 156:321-331.
49. Raijmakers M.T.M., Dechend R., Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension 2004, 44:374-380.
50. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
51. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 2004, 89:770-775.
52. Maynard S.E., Min J.-Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111:649-658.
53. Levine R.J., Lam C., Qian C., et al. The Cpep Study Group, soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006, 355:992-1005.
54. Martin J.N., Rose C.H., Briery C.M. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am. J. Obstet. Gynecol. 2006, 195:914-934.
55. Van Runnard Heimel P.J., Kavelaars A., Heijnen C.J., et al. HELLP syndrome is associated with an increased inflammatory response, which may be inhibited by administration of prednisolone. Hypertens. Pregnancy 2008, 27:253-265.
56. Buimer M., Keijser R., Jebbink J.M., et al. Seven placental transcripts characterize HELLP-syndrome. Placenta 2008, 29:444-453.
57. Widmer M., Villar J., Benigni A., Conde-Agudelo A., Karumanchi S.A., Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet. Gynecol. 2007, 109:168-180.
58. Zusterzeel P.L., Visser W., Peters W.H., Merkus H.W., Nelen W.L., Steegers E.A. Polymorphism in the glutathione S-transferase P1 gene and risk for preeclampsia. Obstet. Gynecol. 2000, 96:50-54.
59. Laivuori H., Gallaher M.J., Collura L., et al. Relationship between maternal plasma leptin, placental leptin mRNA and protein in normal pregnancy, pre-eclampsia and intrauterine growth restriction without preeclampsia. Mol. Hum. Reprod. 2006, 12:551-556.
60. Smith G.C., Stenhouse E.J., Crossley J.A., Aitken D.A., Cameron A.D., Connor J.M. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J. Clin. Endocrinol. Metab. 2002, 87:1762-1767.
61. Bertalan R., Patocs A., Nagy B., et al. Overrepresentation of BclI polymorphism of the glucocorticoid receptor gene in pregnant women with HELLP syndrome. Clin. Chim. Acta 2009, 405:148-152.
62. Rossum E.F., Lamberts S.W. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 2004, 59:333-337.
63. Van Oosten M., Dolhain R.J., Koper J.W., et al. Polymorphisms in the glucocorticoid receptor gene which modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:138-142.
64. Sep S., Verbeek J., Koek G., Smits L., Spaanderman M., Peeters L. Clinical differences between early-onset HELLP syndrome and early onset preeclampsia during pregnancy and at least 6 months postpartum. Am. J. Obstet. Gynecol. 2010, 202:271.e1-271.e5.
65. Leeners B., Rath W., Kuse S., Irawan C., Imthum B., Neumaier-Wagner P. BMI: new aspects of a classical risk factor for hypertensive disorders in pregnancy. Clin. Sci. 2006, 111:81-86.
66. Vinnars M.T., Wijnaendts L.C., Westgren M., Bolte A.C., Papadogiannakis N., Nasiell J. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008, 51:1295-1299.
67. Sailhamer E.A., Li Y., Smith E.J., et al. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 2008, 144:204-216.
68. Knaspen M.F., Mulder T.P., Bisseling J.G., Penders R.R.H., Peters W.H., Steegers E.A. Plasma glutathione S-transferase alpha 1-1: a more sensitive marker for hepatocellular damage than serum alanine aminotransferase in hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 1998, 178:161-165.
69. Takacs P., Green K.L., Nikaeo A., Kauma S.W. Increased vascular endothelial cell production of interleukin-6 in severe preeclampsia. Am. J. Obstet. Gynecol. 2003, 188:740-744.
70. Jarvelainen H., Pelliniemi T.T., Ronnemaa T. The stabilizing effect of glucocorticoids on human endothelial cells in culture. Scand. J. Clin. Lab. Invest. 1985, 45:223-228.
71. Kitchens C.S., Pendergast J.F. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 1986, 67:203-206.
72. Strand S., Strand D., Seufert R., et al. Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. Gastroenterology 2004, 126:849-858.
73. Tranquilli A.L., Landi B., Corradetti A., et al. Inflammatory cytokines patterns in the placenta of pregnancies complicated by HELLP (hemolysis, elevated liver enzymes, and low platelet) syndrome. Cytokine 2007, 40:82-88.
74. Haddad J.J., Saadé N.E., Safieh-Garabedian B. Interleukin-10 and the regulation of mitogen-activated protein kinases: are these signalling modules targets for the anti-inflammatory action of this cytokine?. Cell. Signal. 2003, 15:255-267.
75. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
76. Caniggia I., Grisaru-Granovsky S., Kuliszewsky M., Post M., Lye S.J. Inhibition of TGF-beta3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J. Clin. Invest. 1999, 103:1641-1650.
77. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
78. El Bassam S., Pinsonneault S., Kornfeld H., Ren F., Menezes J., Laberge S.S. Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 2006, 117:89-96.
79. Seely E.W., Solomon C.G. Insulin resistance and its potential role in pregnancy-induced hypertension. J. Clin. Endocrinol. Metab. 2003, 88:2393-2398.
80. Scioscia M., Gumaa K., Rademacher T.W. The link between insulin resistance and preeclampsia: new perspectives. J. Reprod. Immunol. 2009, 82:100-105.
81. Lynch A.M., Murphy J.R., Byers T., et al. Alternative complement pathway activation fragment Bp in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 2008, 198:e1-e9.
82. Girardi G., Yarilin D., Thurman J.M., Holers V.M., Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 2006, 203:2165-2175.
83. Nagy B., Savli H., Molvarec A., et al. Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melting curve analyses. Clin. Chim. Acta 2008, 389:126-131.
84. Abraham K.A., Kennelly M., Dorman A.M., Walshe J.J. Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003, 108:99-102.
85. Fakhouri F., Fremeaux-Bacchi V. Does haemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. Nat. Clin. Pract. Nephrol. 2007, 3:679-687.
86. Lattuada A., Rossi E., Calzarossa C., Candolfi R., Mannucci P.M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003, 88:1029-1034.
87. Tsai H. Current concepts in thrombotic thrombocytopenic purpura. Annu. Rev. Med. 2006, 57:419-436.
88. Fakhouri F., Jablonski M., Lepercq J., et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count. Blood 2008, 112:4542-4545.
89. Tsirigotis P., Mantzios G., Pappa V., et al. Antiphospholipid syndrome: a predisposing factor for early onset HELLP syndrome. Rheumatol. Int. 2007, 28:171-174.
90. Mello G., Parretti E., Marozio L., et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005, 46:1270-1274.
91. Asherson R.A., Glarza-Maldonado C., Sanin-Blair J. The HELLP syndrome, antiphospholipid antibodies, and syndrome. Clin. Rheumatol. 2008, 27:1-4.
92. Salmon J.E., Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J. Reprod. Immunol. 2008, 77:51-56.
93. Holers V.M., Girardi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 2002, 195:211-220.
94. Woita J., Huber K., Valent P. New aspects in thrombotic research: complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol. Haemost. Thromb. 2003, 33:438-441.
95. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partner in crime. Trends Immunol. 2007, 28:184-192.
96. Rezende S.M., Simmonds R.E., Lane D.A. Coagulation, inflammation, and apoptosis: different role for protein S and the protein S-C4b binding protein complex. Blood 2004, 103:1192-1201.
97. Guven S., Sonmez M., Karahan S.C. The role of fibrinolytic and antifibrinolytic activities in the pathophysiology of HELLP syndrome. Hypertens. Pregnancy 2009, 1-14. (epub ahead of print).
98. Solberg H., Rinkemberg J., Dano K., Werb Z., Lund L.R. A functional overlap of plasminogen and MMP's regulates vascularization during placental development. Development 2003, 130:4439-4450.
99. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. 1997, 378:151-160.
100. Floridon C., Nielsen O., Holund B., et al. Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies. Placenta 2000, 21:754-762.
101. Pildner von Steinburg S., Kruger A., Fischer T., Schneider K.-T.M., Schmitt M. Placental expression of proteases and their inhibitors in patients with HELLP syndrome. Biol. Chem. 2009, 390:1199-1204.
102. Walsh S.W. Eicosanoids and preeclampsia. Prostaglandins Leukot. Essent. Fatty Acids 2004, 70:223-232.